Program
4-MUST
Its studies are led by Valenta Pharm JSC.
Furthest: phase 3, since May 12, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valenta Pharm JSC | 33 open or running | phase 3since May 12, 2026 | Feb 17, 2025 | Dec 31, 2026phase 2 · NCT06842966 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2025First study: phase 2 study in Biliary DyskinesiaFirst studyNCT06842966 · 300 planned · Russia
- May 12, 2026Phase 3 study in Biliary DyskinesiaPhase 3 reachedNCT07595003 · 300 planned · Russia
- May 12, 2026Phase 1 study in Biliary DyskinesiaNCT07594977 · 45 planned · Russia
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Biliary DyskinesiaNCT06842966
- Jun 30, 2027Primary completion: phase 1 study in Biliary DyskinesiaNCT07594977
- Dec 31, 2027Primary completion: phase 3 study in Biliary DyskinesiaNCT07595003
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07595003Biliary Dyskinesia · Russia | 3 | Recruiting | Dec 31, 2027 | 300 |
| NCT07594977Biliary Dyskinesia · Russia | 1 | Recruiting | Jun 30, 2027 | 45 |
| NCT06842966Biliary Dyskinesia · Russia | 2 | Recruiting | Dec 31, 2026 | 300 |
How it is read
Names in the registry
- “4-MUST”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.